Predicting arrhythmic risk in arrhythmogenic right ventricular cardiomyopathy: A systematic review and meta-analysis

Publication date

2018-07-01

Authors

Bosman, Laurens P.ORCID 0000-0002-7847-4607
Sammani, Arjan
James, Cynthia A.
Cadrin-Tourigny, Julia
Calkins, Hugh
van Tintelen, J. PeterORCID 0000-0003-3854-6749ISNI 0000000392212598
Hauer, Richard N. W.
Asselbergs, Folkert WORCID 0000-0002-1692-8669ISNI 0000000391548591
te Riele, Anneline S. J. M.

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

taverne

Abstract

While many studies evaluate predictors of ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy (ARVC), a systematic review consolidating this evidence is currently lacking. Therefore, we searched MEDLINE and Embase for studies analyzing predictors of ventricular arrhythmias (sustained ventricular tachycardia/fibrillation (VT/VF), appropriate implantable cardioverter-defibrillator therapy, or sudden cardiac death) in patients with definite ARVC, patients with borderline ARVC, and ARVC-associated mutation carriers. In the case of multiple publications on the same cohort, the study with the largest population was included. This yielded 45 studies with a median cohort size of 70 patients (interquartile range 60 patients) and a median follow-up of 5.0 years (interquartile range 3.3 - 6.7 years). The average proportion of arrhythmic events observed was 10.6%/y in patients with definite ARVC, 10.0%/y in patients with borderline ARVC, and 3.7%/y with mutation carriers. Predictors of ventricular arrhythmias were population dependent: consistently predictive risk factors in patients with definite ARVC were male sex, syncope, T-wave inversion in lead >V3, right ventricular dysfunction, and prior (non)sustained VT/VF; in patients with borderline ARVC, 2 additional predictors—inducibility during electrophysiology study and strenuous exercise—were identified; and with mutation carriers, all aforementioned predictors as well as ventricular ectopy, multiple ARVC-related pathogenic mutations, left ventricular dysfunction, and palpitations/presyncope determined arrhythmic risk. Most evidence originated from small observational cohort studies, with a moderate quality of evidence. In conclusion, the average risk of ventricular arrhythmia ranged from 3.7 to 10.6%/y depending on the population with ARVC. Male sex, syncope, T-wave inversion in lead >V3, right ventricular dysfunction, and prior (non)sustained VT/VF consistently predict ventricular arrhythmias in all populations with ARVC.

Keywords

Arrhythmogenic right ventricular cardiomyopathy, Arrhythmogenic right ventricular dysplasia/cardiomyopathy, Meta-analysis, Prognosis, Risk stratification, Sudden cardiac death, Systematic review, Ventricular arrhythmias, Humans, Risk Factors, Arrhythmogenic Right Ventricular Dysplasia/diagnosis, Electrocardiography, Risk Assessment/methods, Cardiac Resynchronization Therapy Devices, Taverne, Cardiology and Cardiovascular Medicine, Physiology (medical), Research Support, Non-U.S. Gov't, Meta-Analysis, Journal Article

Citation

Bosman, L P, Sammani, A, James, C A, Cadrin-Tourigny, J, Calkins, H, van Tintelen, J P, Hauer, R N W, Asselbergs, F W & te Riele, A S J M 2018, 'Predicting arrhythmic risk in arrhythmogenic right ventricular cardiomyopathy : A systematic review and meta-analysis', Heart Rhythm, vol. 15, no. 7, pp. 1097-1107. https://doi.org/10.1016/j.hrthm.2018.01.031